<DOC>
	<DOCNO>NCT00946569</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness daily oral administration JNJ-39758979 treatment adult ( 18 65 year age ) persistent asthma .</brief_summary>
	<brief_title>A Study Safety Effectiveness JNJ-39758979 Treatment Adults With Persistent Asthma</brief_title>
	<detailed_description>This multicenter , double-blind ( neither physician participant know treatment participant receives ) , randomize ( study medication assign chance ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) , parallel group ( group participant treat time ) , exploratory study ( JNJ-39758979 introduce participant asthma first time ) . This study consist 4 phase : screening phase ( 4 week prior start run-in period ) , placebo run-in phase ( 2 week prior start treatment phase ) , double-blind treatment phase ( 12 week ) , posttreatment phase ( 5 week ) . Approximately 100 participant randomly allocate 1 2 treatment group : Treatment A ( participant receive JNJ-39758979 daily ) treatment B ( participant receive placebo daily ) . Safety evaluate assessment adverse event , clinical laboratory test , vital sign , physical examination , 12-lead electrocardiogram . Total study duration participant approximately 23 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Confirmed diagnosis asthma least 6 month Shortacting betaagonist use great equal 5 time 2 week prior screen Healthy basis physical examination , medical history , vital sign , 12 lead ECG perform screen Having adequate laboratory value No history of/active latent tuberculosis Agree use protocol define contraceptive method History lifethreatening asthma attack require hospitalization asthma within 5 year screen , emergency department treatment asthma within last month Moderate severe renal insufficiency Cigarette smoking within last year Viral bacterial vaccination within last month ( eg , FluMist ) Human Immunodeficiency Virus ( HIV ) Hepatitis B C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Persistent asthma</keyword>
	<keyword>Adults persistent asthma</keyword>
	<keyword>Chronic asthma</keyword>
	<keyword>JNJ-39758979</keyword>
	<keyword>Placebo</keyword>
</DOC>